Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

ACET 09.30.2024

Full Press ReleaseSEC FilingsOur ACET Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
  • 12.31.2024 - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  • 12.19.2024 - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Recent Filings

  • 12.19.2024 - EX-99.1 EX-99.1
  • 12.19.2024 - 8-K Current report
PDF Version

REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Sep. 30, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking placeOctober 16– 17, 2024, inPhiladelphia, PA.

Details of the oral presentation are as follows:

Title:ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology IndicationsSessionName:Novel Targets and Effector CellsAbstract Number:8Presenting Author:Shon Green, Ph.D.Date and Time:October 17, 2024;11:15 a.m.–11:30 a.m. ET

AboutAdicet Bio, Inc.

Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20240930541778/en/

Adicet Bio, Inc.Investors:Anne Bowdidgeabowdidge@adicetbio.com

Janhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com

Media:Kerry Beth Dalykbdaly@adicetbio.com

Source:Adicet Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com